Short‐term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease
Identifieur interne : 005260 ( Main/Exploration ); précédent : 005259; suivant : 005261Short‐term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease
Auteurs : Mario Zappia [Italie] ; Rita Montesanti [Italie] ; Rosanna Colao [Italie] ; Damiano Branca [Italie] ; Giuseppe Nicoletti [Italie] ; Umberto Aguglia [Italie] ; Quattrone [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-01.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (diagnostic use), Antiparkinson agent, Chemotherapy, Drug Administration Schedule, Female, Human, Humans, Levodopa, Levodopa (administration & dosage), Levodopa (diagnostic use), Long-Term Care, Male, Middle Aged, Movement time, Neurologic Examination (drug effects), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Prognosis, Psychomotor Performance (drug effects), Psychomotor Performance (physiology), Reaction Time (drug effects), Reaction Time (physiology), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Short term, Test, Treatment, Treatment efficiency.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , diagnostic use : Antiparkinson Agents, Levodopa.
- diagnosis : Parkinson Disease.
- drug effects : Neurologic Examination, Psychomotor Performance, Reaction Time, Receptors, Dopamine.
- drug therapy : Parkinson Disease.
- physiology : Psychomotor Performance, Reaction Time, Receptors, Dopamine.
- physiopathology : Parkinson Disease.
- Aged, Drug Administration Schedule, Female, Humans, Long-Term Care, Male, Middle Aged, Prognosis.
Abstract
Short‐term challenges with dopaminergic agents are used in patients with idiopathic Parkinson's disease (IPD) to predict the therapeutic effect of sustained levodopa treatment, but false‐negative results often occur. We prospectively evaluated 74 patients with clinically diagnosed IPD and compared the predictive value of a short‐term levodopa test assessed by movement time (MT) with the predictive value obtained by the evaluation with the motor examination part of the Unified Parkinson's Disease Rating Scale (UPDRS‐ME). The response to long‐term levodopa was accurately predicted in 96% of patients by assessing the response to the short‐term test with MT and in 80% of cases with UPDRS‐ME. Similar predictive values were obtained by separately analyzing 21 de novo patients. The short‐term test also accurately predicted the magnitude of improvement with long‐term treatment. We conclude that the predictive value for long‐term dopaminergic responsiveness may be further enhanced by evaluating the short‐term pharmacologic challenges with MT analysis. This is particularly useful to select de novo patients for drug trials with dopaminergic agents.
Url:
DOI: 10.1002/mds.870120118
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002C38
- to stream Istex, to step Curation: 002C38
- to stream Istex, to step Checkpoint: 003883
- to stream PubMed, to step Corpus: 004724
- to stream PubMed, to step Curation: 004724
- to stream PubMed, to step Checkpoint: 004575
- to stream Ncbi, to step Merge: 004C59
- to stream Ncbi, to step Curation: 004C59
- to stream Ncbi, to step Checkpoint: 004C59
- to stream Main, to step Merge: 008288
- to stream PascalFrancis, to step Corpus: 003293
- to stream PascalFrancis, to step Curation: 003531
- to stream PascalFrancis, to step Checkpoint: 003152
- to stream Main, to step Merge: 008507
- to stream Main, to step Curation: 005260
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Short‐term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease</title><author><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name></author><author><name sortKey="Montesanti, Rita" sort="Montesanti, Rita" uniqKey="Montesanti R" first="Rita" last="Montesanti">Rita Montesanti</name></author><author><name sortKey="Colao, Rosanna" sort="Colao, Rosanna" uniqKey="Colao R" first="Rosanna" last="Colao">Rosanna Colao</name></author><author><name sortKey="Branca, Damiano" sort="Branca, Damiano" uniqKey="Branca D" first="Damiano" last="Branca">Damiano Branca</name></author><author><name sortKey="Nicoletti, Giuseppe" sort="Nicoletti, Giuseppe" uniqKey="Nicoletti G" first="Giuseppe" last="Nicoletti">Giuseppe Nicoletti</name></author><author><name sortKey="Aguglia, Umberto" sort="Aguglia, Umberto" uniqKey="Aguglia U" first="Umberto" last="Aguglia">Umberto Aguglia</name></author><author><name sortKey="Quattrone" sort="Quattrone" uniqKey="Quattrone" last="Quattrone">Quattrone</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DCACC02C6F715D30828956BB402BFF8EC3AE4E3C</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120118</idno><idno type="url">https://api.istex.fr/document/DCACC02C6F715D30828956BB402BFF8EC3AE4E3C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002C38</idno><idno type="wicri:Area/Istex/Curation">002C38</idno><idno type="wicri:Area/Istex/Checkpoint">003883</idno><idno type="wicri:doubleKey">0885-3185:1997:Zappia M:short:term:levodopa</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8990062</idno><idno type="wicri:Area/PubMed/Corpus">004724</idno><idno type="wicri:Area/PubMed/Curation">004724</idno><idno type="wicri:Area/PubMed/Checkpoint">004575</idno><idno type="wicri:Area/Ncbi/Merge">004C59</idno><idno type="wicri:Area/Ncbi/Curation">004C59</idno><idno type="wicri:Area/Ncbi/Checkpoint">004C59</idno><idno type="wicri:doubleKey">0885-3185:1997:Zappia M:short:term:levodopa</idno><idno type="wicri:Area/Main/Merge">008288</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:97-0142929</idno><idno type="wicri:Area/PascalFrancis/Corpus">003293</idno><idno type="wicri:Area/PascalFrancis/Curation">003531</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003152</idno><idno type="wicri:doubleKey">0885-3185:1997:Zappia M:short:term:levodopa</idno><idno type="wicri:Area/Main/Merge">008507</idno><idno type="wicri:Area/Main/Curation">005260</idno><idno type="wicri:Area/Main/Exploration">005260</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Short‐term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease</title><author><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea><wicri:noRegion>University of Reggio Calabria</wicri:noRegion></affiliation></author><author><name sortKey="Montesanti, Rita" sort="Montesanti, Rita" uniqKey="Montesanti R" first="Rita" last="Montesanti">Rita Montesanti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea><wicri:noRegion>University of Reggio Calabria</wicri:noRegion></affiliation></author><author><name sortKey="Colao, Rosanna" sort="Colao, Rosanna" uniqKey="Colao R" first="Rosanna" last="Colao">Rosanna Colao</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea><wicri:noRegion>University of Reggio Calabria</wicri:noRegion></affiliation></author><author><name sortKey="Branca, Damiano" sort="Branca, Damiano" uniqKey="Branca D" first="Damiano" last="Branca">Damiano Branca</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea><wicri:noRegion>University of Reggio Calabria</wicri:noRegion></affiliation></author><author><name sortKey="Nicoletti, Giuseppe" sort="Nicoletti, Giuseppe" uniqKey="Nicoletti G" first="Giuseppe" last="Nicoletti">Giuseppe Nicoletti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea><wicri:noRegion>University of Reggio Calabria</wicri:noRegion></affiliation></author><author><name sortKey="Aguglia, Umberto" sort="Aguglia, Umberto" uniqKey="Aguglia U" first="Umberto" last="Aguglia">Umberto Aguglia</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea><wicri:noRegion>University of Reggio Calabria</wicri:noRegion></affiliation></author><author><name sortKey="Quattrone" sort="Quattrone" uniqKey="Quattrone" last="Quattrone">Quattrone</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea><wicri:noRegion>University of Reggio Calabria</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-01">1997-01</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="103">103</biblScope><biblScope unit="page" to="106">106</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DCACC02C6F715D30828956BB402BFF8EC3AE4E3C</idno><idno type="DOI">10.1002/mds.870120118</idno><idno type="ArticleID">MDS870120118</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (diagnostic use)</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Drug Administration Schedule</term><term>Female</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (diagnostic use)</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Movement time</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Prognosis</term><term>Psychomotor Performance (drug effects)</term><term>Psychomotor Performance (physiology)</term><term>Reaction Time (drug effects)</term><term>Reaction Time (physiology)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Short term</term><term>Test</term><term>Treatment</term><term>Treatment efficiency</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term><term>Psychomotor Performance</term><term>Reaction Time</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Psychomotor Performance</term><term>Reaction Time</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Court terme</term><term>Efficacité traitement</term><term>Essai</term><term>Homme</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Essai</term><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Short‐term challenges with dopaminergic agents are used in patients with idiopathic Parkinson's disease (IPD) to predict the therapeutic effect of sustained levodopa treatment, but false‐negative results often occur. We prospectively evaluated 74 patients with clinically diagnosed IPD and compared the predictive value of a short‐term levodopa test assessed by movement time (MT) with the predictive value obtained by the evaluation with the motor examination part of the Unified Parkinson's Disease Rating Scale (UPDRS‐ME). The response to long‐term levodopa was accurately predicted in 96% of patients by assessing the response to the short‐term test with MT and in 80% of cases with UPDRS‐ME. Similar predictive values were obtained by separately analyzing 21 de novo patients. The short‐term test also accurately predicted the magnitude of improvement with long‐term treatment. We conclude that the predictive value for long‐term dopaminergic responsiveness may be further enhanced by evaluating the short‐term pharmacologic challenges with MT analysis. This is particularly useful to select de novo patients for drug trials with dopaminergic agents.</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name></noRegion><name sortKey="Aguglia, Umberto" sort="Aguglia, Umberto" uniqKey="Aguglia U" first="Umberto" last="Aguglia">Umberto Aguglia</name><name sortKey="Branca, Damiano" sort="Branca, Damiano" uniqKey="Branca D" first="Damiano" last="Branca">Damiano Branca</name><name sortKey="Colao, Rosanna" sort="Colao, Rosanna" uniqKey="Colao R" first="Rosanna" last="Colao">Rosanna Colao</name><name sortKey="Montesanti, Rita" sort="Montesanti, Rita" uniqKey="Montesanti R" first="Rita" last="Montesanti">Rita Montesanti</name><name sortKey="Nicoletti, Giuseppe" sort="Nicoletti, Giuseppe" uniqKey="Nicoletti G" first="Giuseppe" last="Nicoletti">Giuseppe Nicoletti</name><name sortKey="Quattrone" sort="Quattrone" uniqKey="Quattrone" last="Quattrone">Quattrone</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005260 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005260 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DCACC02C6F715D30828956BB402BFF8EC3AE4E3C
|texte= Short‐term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |